In vitro evaluation of the potential use of snake-derived peptides in the treatment of respiratory infections using inhalation therapy: A proof of concept study

Eur J Pharm Sci. 2023 Apr 1:183:106398. doi: 10.1016/j.ejps.2023.106398. Epub 2023 Feb 3.

Abstract

Inhalation therapy using nebulisers is an attractive non-invasive route for drug delivery, particularly for the treatment of lung infections with anti-inflammatory and anti-microbial compounds. This study evaluated the suitability of three snake-derived peptides (termed Sn1b, SnE1 and SnE1-F), which we have recently shown have potent anti-inflammatory and bacteriostatic activities, for nebulisation using a vibrating mesh nebuliser (VMN). The effect of nebulisation on peptide concentration, stability and function were assessed, prior to progression to aerodynamic particle size distribution, and in vitro drug delivery in simulated adult spontaneous breathing and mechanical ventilated patient models. When nebulised, all three peptides exhibited similar functions to their non-nebulised counterparts and were found to be respirable during simulated mechanical ventilation. Based on the assessment of the droplet distributions of nebulised peptides using a Next Generation Impactor (NGI) demonstrated that if administered in vivo each peptide would likely be delivered to the lower airways. These data suggest that nebulisation using a VMN is a viable means of anti-microbial / anti-inflammatory peptide delivery targeting microbial respiratory infections, and possibly even systemic infections.

Keywords: Anti-bacterial; Anti-inflammatory; Nebulisation; Peptide.

MeSH terms

  • Administration, Inhalation
  • Adult
  • Humans
  • Nebulizers and Vaporizers
  • Peptides
  • Proof of Concept Study
  • Respiratory Aerosols and Droplets
  • Respiratory Therapy*
  • Respiratory Tract Infections*

Substances

  • Peptides